The study, registered as NCT07862647, aims to address a patient population frequently excluded from traditional glioblastoma trials due to the tumor's diffuse, bilateral spread. With a median survival rate of just three to six months, butterfly glioblastoma often renders surgical resection impossible. Dr. David Reardon of the Dana-Farber Cancer Institute noted that the condition’s distribution demands a departure from standard oncology practices, highlighting the need for targeted strategies that span both hemispheres.

Alpheus Medical’s PoMA therapy involves the oral administration of 5-aminolevulinic acid, which accumulates in tumor cells. Once localized, the substance is activated by low-intensity defocused ultrasound while the patient remains awake in an outpatient setting. The Dent Neurologic Institute in Buffalo, New York, is currently the active site, with plans to expand to additional U.S. centers. CEO Dr. Vijay Agarwal emphasized that the time-sensitive nature of the treatment requires clinicians and patients to initiate contact early in their care journey. Interested parties can review eligibility and site locations at www.BrainCancerTrial.com.